Mizuho analyst Joseph Catanzaro initiated coverage of Avalo Therapeutics (AVTX) with an Outperform rating and $39 price target The firm believes the company’s lead program AVTX-009 is well positioned for a positive Phase II readout in hidradenitis suppurativa in mid-2026. It projects $1B in risk-adjusted 2035 worldwide sales for AVTX-009 and expects positive Phase II data to drive share outperformance.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Completes Enrollment for Phase 2 LOTUS Trial
- Avalo Therapeutics Reports Q3 2025 Financial Results
- Avalo Therapeutics reports Q3 EPS ($2.19), consensus ($1.64)
- Avalo Therapeutics completes enrollment in Phase 2 LOTUS trial
- Avalo Therapeutics Advances in Hidradenitis Suppurativa Treatment with AVTX-009 Study